LPIN3 promotes colorectal cancer growth by dampening intratumoral CD8+ T cell effector function.

IF 5.1 2区 医学 Q2 IMMUNOLOGY Cancer Immunology, Immunotherapy Pub Date : 2025-03-05 DOI:10.1007/s00262-025-03989-2
Xiaoming Zhang, Hao Fang, Wenliang Wu, Congqing Jiang, Haizhou Wang, Yifei Shi
{"title":"LPIN3 promotes colorectal cancer growth by dampening intratumoral CD8<sup>+</sup> T cell effector function.","authors":"Xiaoming Zhang, Hao Fang, Wenliang Wu, Congqing Jiang, Haizhou Wang, Yifei Shi","doi":"10.1007/s00262-025-03989-2","DOIUrl":null,"url":null,"abstract":"<p><p>LPIN3 has emerged as a key factor in a variety of malignancies, although its precise role in colorectal cancer (CRC) remains unclear. By analyzing the data from The Cancer Genome Atlas, we discovered that the expression pattern of LPIN3 and the relevant makeup of the immune microenvironment were immensely diverse among tumors. LPIN3 is abundantly expressed in CRC and may enhance tumor growth by activating the β-catenin signaling pathway. In addition, we discovered that LPIN3 might reduce tumor antigen presentation signals, hence suppressing CD8<sup>+</sup> T cell-mediated cytotoxicity. Furthermore, high expression of LPIN3 predicts decreased CD8<sup>+</sup> T cell infiltration and effector function via bioinformatics analysis. Indeed, CD8<sup>+</sup> T cell-mediated cytotoxicity as well as CD8<sup>+</sup> T cell infiltration and activation in vivo were strengthened by LPIN3 knockdown. To sum up, our results highlight the part that LPIN3 plays in driving the progression of CRC by regulating β-catenin signaling and CD8<sup>+</sup> T cell activity.</p>","PeriodicalId":9595,"journal":{"name":"Cancer Immunology, Immunotherapy","volume":"74 4","pages":"135"},"PeriodicalIF":5.1000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11883066/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Immunology, Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00262-025-03989-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

LPIN3 has emerged as a key factor in a variety of malignancies, although its precise role in colorectal cancer (CRC) remains unclear. By analyzing the data from The Cancer Genome Atlas, we discovered that the expression pattern of LPIN3 and the relevant makeup of the immune microenvironment were immensely diverse among tumors. LPIN3 is abundantly expressed in CRC and may enhance tumor growth by activating the β-catenin signaling pathway. In addition, we discovered that LPIN3 might reduce tumor antigen presentation signals, hence suppressing CD8+ T cell-mediated cytotoxicity. Furthermore, high expression of LPIN3 predicts decreased CD8+ T cell infiltration and effector function via bioinformatics analysis. Indeed, CD8+ T cell-mediated cytotoxicity as well as CD8+ T cell infiltration and activation in vivo were strengthened by LPIN3 knockdown. To sum up, our results highlight the part that LPIN3 plays in driving the progression of CRC by regulating β-catenin signaling and CD8+ T cell activity.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
LPIN3通过抑制肿瘤内CD8+ T细胞效应功能促进结直肠癌的生长。
LPIN3已成为多种恶性肿瘤的关键因子,尽管其在结直肠癌(CRC)中的确切作用尚不清楚。通过分析来自the Cancer Genome Atlas的数据,我们发现LPIN3的表达模式和相关的免疫微环境组成在肿瘤中存在极大的差异。LPIN3在结直肠癌中大量表达,可能通过激活β-catenin信号通路促进肿瘤生长。此外,我们发现LPIN3可能降低肿瘤抗原呈递信号,从而抑制CD8+ T细胞介导的细胞毒性。此外,通过生物信息学分析,LPIN3的高表达预示着CD8+ T细胞浸润和效应功能的降低。事实上,CD8+ T细胞介导的细胞毒性以及体内CD8+ T细胞的浸润和活化被LPIN3敲低增强。综上所述,我们的研究结果强调了LPIN3通过调节β-catenin信号传导和CD8+ T细胞活性在驱动CRC进展中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
文献相关原料
公司名称
产品信息
索莱宝
DNase I
索莱宝
puromycin
来源期刊
CiteScore
10.50
自引率
1.70%
发文量
207
审稿时长
1 months
期刊介绍: Cancer Immunology, Immunotherapy has the basic aim of keeping readers informed of the latest research results in the fields of oncology and immunology. As knowledge expands, the scope of the journal has broadened to include more of the progress being made in the areas of biology concerned with biological response modifiers. This helps keep readers up to date on the latest advances in our understanding of tumor-host interactions. The journal publishes short editorials including "position papers," general reviews, original articles, and short communications, providing a forum for the most current experimental and clinical advances in tumor immunology.
期刊最新文献
NECTIN4 regulates the cell surface expression of CD155 in non-small cell lung cancer cells and induces tumor resistance to PD-1 inhibitors. Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma. Unraveling the complex role of tumor-associated neutrophils within solid tumors. Carry-over effect of immunotherapy in patients with advanced hepatocellular carcinoma. Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescence.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1